263 related articles for article (PubMed ID: 22390757)
1. Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.
Thanapprapasr D; Hu W; Sood AK; Coleman RL
Curr Pharm Des; 2012; 18(19):2713-9. PubMed ID: 22390757
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.
Frumovitz M; Sood AK
Gynecol Oncol; 2007 Mar; 104(3):768-78. PubMed ID: 17306693
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis Markers in Gynecological Tumors and Patents for Anti-Angiogenic Approach: Review.
Abdalla DR; Simoens C; Bogers JP; Murta EF; Michelin MA
Recent Pat Anticancer Drug Discov; 2015; 10(3):298-307. PubMed ID: 26381660
[TBL] [Abstract][Full Text] [Related]
4. Strategies for suppressing angiogenesis in gynecological cancers.
Ma WW; Jimeno A
Drugs Today (Barc); 2007 Apr; 43(4):259-73. PubMed ID: 17460787
[TBL] [Abstract][Full Text] [Related]
5. Targeting angiogenesis in gynecologic cancers.
Zand B; Coleman RL; Sood AK
Hematol Oncol Clin North Am; 2012 Jun; 26(3):543-63, viii. PubMed ID: 22520979
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic agents in natural products for the treatment of gynecologic disorders.
Aghamohammadi A; Hosseinimehr SJ
Nutr Cancer; 2014; 66(2):206-13. PubMed ID: 24410431
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.
Yetkin-Arik B; Kastelein AW; Klaassen I; Jansen CHJR; Latul YP; Vittori M; Biri A; Kahraman K; Griffioen AW; Amant F; Lok CAR; Schlingemann RO; van Noorden CJF
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188446. PubMed ID: 33058997
[TBL] [Abstract][Full Text] [Related]
8. Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers.
Schmid BC; Oehler MK
Curr Treat Options Oncol; 2015 Jan; 16(1):318. PubMed ID: 25750175
[TBL] [Abstract][Full Text] [Related]
9. Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment.
Wei XW; Zhang ZR; Wei YQ
Expert Opin Investig Drugs; 2013 Sep; 22(9):1181-92. PubMed ID: 23782133
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets.
Rasila KK; Burger RA; Smith H; Lee FC; Verschraegen C
Int J Gynecol Cancer; 2005; 15(5):710-26. PubMed ID: 16174217
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
13. The merits of vascular targeting for gynecologic malignancies.
Kamat AA; Sood AK
Curr Oncol Rep; 2005 Nov; 7(6):444-50. PubMed ID: 16221381
[TBL] [Abstract][Full Text] [Related]
14. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
16. Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.
Tomao F; Papa A; Rossi L; Caruso D; Zoratto F; Benedetti Panici P; Tomao S
Expert Opin Investig Drugs; 2014 Jan; 23(1):37-53. PubMed ID: 24111925
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies in gynecologic cancers.
Chon HS; Hu W; Kavanagh JJ
Curr Cancer Drug Targets; 2006 Jun; 6(4):333-63. PubMed ID: 16848724
[TBL] [Abstract][Full Text] [Related]
18. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
[TBL] [Abstract][Full Text] [Related]
19. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling.
Gao J; Hu H; Wang X
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1007-1015. PubMed ID: 30887179
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis in malignancies of the female genital tract.
Abulafia O; Triest WE; Sherer DM
Gynecol Oncol; 1999 Feb; 72(2):220-31. PubMed ID: 10021305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
